Dispensing profile of botulinum toxin for treating spasticity: Brazilian national data

Authors

  • Tae Mo Chung Universidade de São Paulo. Faculdade de Medicina. Hospital das Clinicas. Instituto de Medicina Física e Reabilitação
  • Adriana Moro Universidade Federal do Paraná. Hospital de Clínicas.
  • Ana Paula Coutinho Fonseca Instituto de Fisiatria, Reabilitação e Tratamento da Dor
  • Arquimedes de Moura Ramos Universidade de São Paulo. Faculdade de Medicina. Hospital das Clinicas. Instituto de Medicina Física e Reabilitação
  • Cristiane Lima Carqueja Centro Catarinense de Reabilitação
  • Denise Rodriques Xerez Hospital Universitário Clementino Fraga Filho. Serviço de Medicina Física e Reabilitação
  • Eduardo Freire de Oliveira Universidade de São Paulo. Faculdade de Medicina. Hospital das Clinicas. Instituto de Medicina Física e Reabilitação
  • Gláucia Somensi de Oliveira Alonso Associação de Assistência à Criança Deficiente
  • Lucia Helena Costa Mercuri Granero Universidade Federal de São Paulo
  • Luiz Antonio de Arruda Botelho Universidade Federal de São Paulo. Setor de Bloqueio Químicos
  • Maurício Rassi Centro de Reabilitação e Readaptação Dr Henrique Santillo
  • Patrícia Zambone da Silva Pontifícia Universidade Católica do Rio Grande do Sul. Hospital São Lucas
  • Sérgio Lianza Santa Casa de São Paulo. Faculdade de Ciências Médicas. Departamento de Ortopedia
  • Sonia Maria Carneiro Chaves Centro Médico e de Reabilitação Guilherme Chaves

DOI:

https://doi.org/10.5935/0104-7795.20160001

Keywords:

Botulinum Toxins, Muscle Spasticity/rehabilitation, Public Health Policy, Brazil

Abstract

The physiatrists specialized in treating spasticity were brought together for a panel discussion about the use of botulinum toxin (BT) in the public system in different states of Brazil. The data analyzed during the discussion of Datasus demonstrate a low-demand profile of the product dispensed by the Unified Health System (SUS), with heterogeneity in the distribution of TB in the Brazilian states. This scenario seems to be set up mainly for lack of a properly planned public policy, such as lack of unification and standardization of distribution centers, the lack or inadequacy of TB compensation proceeding to treatment centers, in a standardized manner by SUS and shortage of trained doctors to do it together with the lack of qualified multidisciplinary rehabilitation centers. The use of botulinum toxin for therapeutic purposes in Brazil began in the 90s, to treat dystonia and spasticity. It is currently employed in different clinical conditions; however, despite growing demand and indications over the years, there are few reports or publications on its use and benefit to patients served by the Unified Health System (SUS). To address this issue, in May 2015, in São Paulo, physiatrists from different states of Brazil met and discussed the relevance of botulinum toxin in treating spasticity.

Downloads

Download data is not yet available.

References

Shaw L, Rodgers H, Price C, van Wijck F, Shackley P, Steen N, et al. BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technol Assess. 2010;14(26):1-113. DOI: http://dx.doi.org/10.3310/hta14260

Koman LA, Paterson Smith B, Balkrishnan R. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. Paediatr Drugs. 2003;5(1):11-23. DOI: http://dx.doi.org/10.2165/00128072-200305010-00002

Bergfeldt U, Sköld C, Julin P. Short Form 36 assessed health-related quality of life after focal spasticity therapy. J Rehabil Med. 2009;41(4):279-81. DOI: http://dx.doi.org/10.2340/16501977-0318

Cardoso E, Rodrigues B, Lucena R, Oliveira IR, Pedreira G, Melo A. Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis. Arq Neuropsiquiatr. 2005;63(1):30-3. DOI: http://dx.doi.org/10.1590/S0004-282X2005000100006

Assis TR, Forlin E, Bruck I, Antoniuk SA, Santos LH. Quality of life of children with cerebral palsy treated with botulinum toxin: are well-being measures appropriate? Arq Neuropsiquiatr. 2008;66(3B):652-8. DOI: http://dx.doi.org/10.1590/S0004-282X2008000500009

Charles PD, Gill CE, Taylor HM, Putman MS, Blair CR, Roberts AG, et al. Spasticity treatment facilitates direct care delivery for adults with profound intellectual disability. Mov Disord. 2010;25(4):466-73. DOI: http://dx.doi.org/10.1002/mds.22995

Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, et al. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil. 2008;89(5):799-806. DOI: http://dx.doi.org/10.1016/j.apmr.2008.01.007

Cardoso E, Pedreira G, Prazeres A, Ribeiro N, Melo A. Does botulinum toxin improve the function of the patient with spasticity after stroke? Arq Neuropsiquiatr. 2007;65(3A):592-5. DOI: http://dx.doi.org/10.1590/S0004-282X2007000400008

Boyne P, Dunning K, Levine P, Hermann VH, Page SJ. Orthotic functional electrical stimulation following botulinum toxin for a young adult with severe hand impairment due to childhood stroke. Physiother Theory Pract. 2010;26(4):267-74. DOI: http://dx.doi.org/10.3109/09593980902967188

Rosales RL, Kanovsky P, Fernandez HH. What's the "catch" in upper-limb post-stroke spasticity: expanding the role of botulinum toxin applications. Parkinsonism Relat Disord. 2011;17 Suppl 1:S3-10. DOI: http://dx.doi.org/10.1016/j.parkreldis.2011.06.019

Brasil. Ministério da Saúde. Portaria n. 377 de 10 de novembro de 2009. Estabelece parâmetros sobre a espasticidade no Brasil e diretrizes nacionais para diagnóstico, tratamento e acompanhamento dos indivíduos com esta doença [texto na Internet]. Diário Oficial da República Federativa do Brasil, Brasília (DF); 2009 Nov 11 [citado 2016 Jan 10]. Disponível em: http://bvsms.saude.gov.br/bvs/saudelegis/gm/2013/prt2979_04_12_2013.html

Desloovere K, Molenaers G, De Cat J, Pauwels P, Van Campenhout A, Ortibus E, et al. Motor function following multilevel botulinum toxin type A treatment in children with cerebral palsy. Motor function following multilevel botulinum toxin type A treatment in children with cerebral palsy. Dev Med Child Neurol. 2007;49(1):56-61. DOI: http://dx.doi.org/10.1017/S001216220700014X.x

Pedreira G, Cardoso E, Melo A. Botulinum toxin type A for refractory post-stroke shoulder pain. Arq Neuropsiquiatr. 2008;66(2A):213-5. DOI: http://dx.doi.org/10.1590/S0004-282X2008000200014

Cameron MH, Bethoux F, Davis N, Frederick M. Botulinum toxin for symptomatic therapy in multiple sclerosis. Curr Neurol Neurosci Rep. 2014;14(8):463. DOI: http://dx.doi.org/10.1007/s11910-014-0463-7

Edgar TS. Clinical utility of botulinum toxin in the treatment of cerebral palsy: comprehensive review. J Child Neurol. 2001;16(1):37-46. DOI: http://dx.doi.org/10.1177/088307380101600107

Sposito MMM. Toxina Botulínica do Tipo A: mecanismo de açao. Acta Fisiatr. 2009;16(1):25-37.

Khalili AA, Harmel MH, Forster S, Benton JG. Management of spasticity by selective peripheral nerve block with dilute phenol solutions in clinical rehabilitation. Arch Phys Med Rehabil. 1964;45:513-9.

Gooch JL, Patton CP. Combining botulinum toxin and phenol to manage spasticity in children. Arch Phys Med Rehabil. 2004;85(7):1121-4. DOI: http://dx.doi.org/10.1016/j.apmr.2003.09.032

Botelho LAA, Granero LHC, Masiero D. A neurólise química simultânea com Fenol e Toxina Botulínica do tipo A para o tratamento da espasticidade em sessenta e sete pacientes. Med Reabil. 2002;59:20-4.

Lianza S, Pavan K, Lourenço AF, Fonseca AP, Leitao AV, Musse CAI, et al. Diagnóstico e tratamento da espasticidade [texto na Internet]. São Paulo: AMB/CFM [citado 2016 Jan 10]. Disponível em: http://projetodiretrizes.org.br/projeto_diretrizes/048.pdf

Brasil. Ministério da Saúde. Portaria n. 2.979 de 04 de dezembro de 2013. Estabelece processo de aquisição centralizada pelo Ministério da Saúde dos medicamentos toxina botulínica tipo A 100u injetável - por frasco-ampola, do componente especializado da assistência farmacêutica [texto na Internet]. Diário Oficial da República Federativa do Brasil, Brasília (DF); 2013 Dez 12 [citado 2016 Jan 10]. Disponível em: http://bvsms.saude.gov.br/bvs/saudelegis/gm/2013/prt2979_04_12_2013.html

Downloads

Published

2016-03-07

Issue

Vol. 23 No. 1 (2016)

Section

Original Article

License

Copyright (c) 2016 Acta Fisiátrica

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite

1.
Chung TM, Moro A, Fonseca APC, Ramos A de M, Carqueja CL, Xerez DR, et al. Dispensing profile of botulinum toxin for treating spasticity: Brazilian national data. Acta Fisiátr. [Internet]. 2016 Mar. 7 [cited 2024 May 16];23(1):1-6. Available from: https://www.revistas.usp.br/actafisiatrica/article/view/137599